Squamous Cell Carcinoma of the Esophagus Completed Phase 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0030042 (Squamous Cell Carcinoma of the Esophagus)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00045526Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach CancerTreatment